LIPONEX GETS HEALTH CANADA APPROVAL TO BEGIN CRD5 TRIAL

Liponex has announced that it has received Health Canada approval to initiate a clinical trial in a patient population using a new formulation of its lead pharmaceutical product, CRD5, being developed for the treatment and prevention of heart disease.

The Phase I/II dose-ranging trial will take place at a leading Canadian academic health sciences center, and will involve 50 dyslipidemic patients (patients with low HDL and high LDL). Following dietary lead in, patients will be given daily doses of the latest formulation of CRD5 in capsule form. The treatment period for each patient will be 12 weeks. The primary endpoints for the trial are safety and an increase in serum HDL, with triglyceride and LDL reductions as secondary endpoints. The results of this trial will be used to determine an optimal dose for use in subsequent trials to confirm the efficacy of CRD5 in larger patient populations.